Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

Germany

Neurocrine Clinical Site, Berlin

Neurocrine Clinical Site, Düsseldorf

Neurocrine Clinical Site, Heidelberg